title: NICE guidance on ipilimumab for treating previously   untreated advanced (unresectable or metastatic) melanoma.
authors.forename: Caroline J
authors.initials: CJ
authors.lastname: Hall
authors.forename: Sally
authors.initials: S
authors.lastname: Doss
authors.forename: Janet
authors.initials: J
authors.lastname: Robertson
authors.forename: Jane
authors.initials: J
authors.lastname: Adam
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D008875:Middle Aged; D009313:National Health Programs / Q000592:standards; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic / Q000592:standards*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D015996:Survival Rate; D016896:Treatment Outcome; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal; D000074324:Ipilimumab